Compare CRNX & ACHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | ACHR |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | 2018 | 2020 |
| Metric | CRNX | ACHR |
|---|---|---|
| Price | $84.78 | $6.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $76.75 | $12.00 |
| AVG Volume (30 Days) | 2.6M | ★ 38.4M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | $300,000.00 |
| Revenue This Year | $720.10 | $4,986.67 |
| Revenue Next Year | $184.67 | $876.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.00 | $4.30 |
| 52 Week High | $84.80 | $14.62 |
| Indicator | CRNX | ACHR |
|---|---|---|
| Relative Strength Index (RSI) | 89.98 | 53.98 |
| Support Level | $83.47 | $5.53 |
| Resistance Level | N/A | $7.37 |
| Average True Range (ATR) | 0.20 | 0.50 |
| MACD | -1.13 | 0.01 |
| Stochastic Oscillator | 98.98 | 45.23 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.